Secondary objectives included determining the correlations between NGAL and eGFR, ferritin, CaP product, and total serum protein, thereby assessing NGAL’s potential role as a biomarker for CKD progression and associated metabolic disturbances. This evidence concerns the gene LCN2 and chronic kidney disease.